The post 1inch and Ondo RWA Volumes Top $2.5B as RWAs Climb appeared on BitcoinEthereumNews.com. Trading volumes in tokenized stocks and exchange-traded funds (The post 1inch and Ondo RWA Volumes Top $2.5B as RWAs Climb appeared on BitcoinEthereumNews.com. Trading volumes in tokenized stocks and exchange-traded funds (

1inch and Ondo RWA Volumes Top $2.5B as RWAs Climb

For feedback or concerns regarding this content, please contact us at [email protected]

Trading volumes in tokenized stocks and exchange-traded funds (ETFs) routed through 1inch’s integration with Ondo have passed $2.5 billion since the partnership went live in September 2025.

According to data published on Dune Analytics and a release shared with Cointelegraph, real-world assets (RWAs) are now the fastest-growing volume category on 1inch. While they still account for a minority of overall flow, 1inch co-founder Sergei Kunz told Cointelegraph that “the direction of travel is clear,” and shows no signs of slowing down, despite the broader crypto slump.

​Most of the activity is happening on BNB (BNB) Chain, where roughly $2 billion in related volume has been generated over 1.3 million transactions, with peak active users nearing 24,800 in a single period. 

RWA statistics: Source: Dune

Kunz said that the combination of a low-friction user experience and massive retail distribution made BNB Chain “the natural place for RWA activity to occur,” adding that it was “happening faster and more retail-sized than on Ethereum (ETH).”

Related: MEXC expands tokenized stock offerings with new Ondo Finance listings

He added that both retail and advanced users were trading RWAs, and that the typical swap size was around $1,400, which he said showed “real capital, deployed with intent” rather than test traffic.

The most popular tokens are currently well-known traditional finance names such as Nvidia ($354 million in volume), Tesla ($332 million), Google ($249 million), and Netflix ($98 million), plus silver among non-equity assets ($225 million).

Tokenized RWAs defy slump as Ethereum nears $15 billion

The milestone comes as tokenized RWAs emerge as one of the few consistent growth stories in crypto. Ethereum’s RWA total value locked (TVL) has climbed to nearly $15 billion, up roughly 200% over the past year.

Tokenized US Treasuries have been a major driver of that growth, with a market cap that has risen by over $1 billion since the start of 2026, a roughly 50x increase since 2024, as products like BlackRock’s BUIDL fund help pull traditional fixed income onchain.

Related: Kraken’s xStocks tops $25B in volume with more than 80K onchain holders

At the same time, tokenized RWAs and the infrastructure behind them have continued to attract fresh capital. RWA tokenization projects were among the biggest winners in crypto venture funding in 2025, while onchain RWA markets climbed roughly 13.5% over 30 days during a period when the wider crypto market shed around $1 trillion in value.

RWAs to become everyday DeFi plumbing

1inch’s Ondo integration shows how aggregators are evolving into distribution rails for regulated RWA issuers. Kunz said 1inch remained non-custodial and did not issue the RWAs itself, with eligibility and jurisdictional controls enforced at the issuer level, while it focuses on routing, application programming interfaces (APIs) and disclosures. 

Looking ahead, Kunz sees RWAs taking “the next leap forward” only when liquidity depth, standards and regulatory clarity align, at which point he expects tokenized assets to function as everyday “financial plumbing on DeFi” rails rather than a niche side bet.

AI Eye: IronClaw rivals OpenClaw, Olas launches bots for Polymarket

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy

Source: https://cointelegraph.com/news/tokenized-rwas-buck-the-slump-1inch-ondo?utm_source=rss_feed&utm_medium=feed&utm_campaign=rss_partner_inbound

Market Opportunity
Allo Logo
Allo Price(RWA)
$0.001994
$0.001994$0.001994
-1.28%
USD
Allo (RWA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09